Leniolisib (Joenja, Pharming) is indicated for 'the treatment of activated phosphoinositide 3‑kinase delta (PI3Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older'. The ...

There is a simple discount patient access scheme for leniolisib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Your organisation needs to be registered as a stakeholder before we can accept comments. Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your ...

Coding and clinical classification codes for this guidance. This guidance replaces NICE interventional procedures guidance on balloon disimpaction of the baby’s head at emergency caesarean during the ...

Section 8(6) of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated ...

The highly specialised technologies evaluation committee is a standing advisory committee of NICE. Committee members are asked to declare any interests in the technology being evaluated. If it is ...

NICE is unable to make a recommendation on tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults. This is because the company did not provide an evidence ...

Tools to help you put the guidance into practice.

Leniolisib (Joenja) is available on the NHS as a possible treatment for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over. Is this treatment right for me? Your healthcare ...

Leniolisib is recommended, within its marketing authorisation, for treating activated phosphoinositide 3‑kinase delta syndrome (APDS) in people 12 years and over. Leniolisib is recommended only if the ...